The FDA has approved Ono’s CSF1R inhibitor vimseltinib (Romvimza) for adults with symptomatic tenosynovial giant cell tumours (TGCT) that are not suitable for surgical resection. It will compete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback